| Identification | Back Directory | [Name]
(1R)-3-AMino-1-[3-(cyclohexylMethoxyl)phenyl]propan-1-ol hydrochloride | [CAS]
1141934-97-5 | [Synonyms]
ACU-4429 Emixustat Emixustat (ACU-4429) ACU-4429 hydrochloride Emixustat Hydrochlorde Emixustat hydrochloride ACU4429;ACU 4429;ACU-4429 (R)-3-Amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol hydrochloride (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol,hydrochloride (1R)-3-AMino-1-[3-(cyclohexylMethoxyl)phenyl]propan-1-ol hydrochloride Benzenemethanol,α-(2-aminoethyl)-3-(cyclohexylmethoxy)-,hydrochloride(1:1),(αR)- | [Molecular Formula]
C16H26ClNO2 | [MDL Number]
MFCD28400873 | [MOL File]
1141934-97-5.mol | [Molecular Weight]
299.836 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:44.0(Max Conc. mg/mL);146.75(Max Conc. mM) | [form ]
A crystalline solid | [color ]
White to off-white | [InChI]
InChI=1/C16H25NO2.ClH/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13;/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2;1H/t16-;/s3 | [InChIKey]
BPZWRYOUJMDQSY-LSQUZMQTNA-N | [SMILES]
[C@@H](C1=CC=CC(OCC2CCCCC2)=C1)(O)CCN.[H]Cl |&1:0,r| |
| Hazard Information | Back Directory | [Uses]
Emixustat (ACU-4429) hydrochloride is an orally active RPE65 inhibitor with an IC50 value of 4.4 nM. Emixustat hydrochloride is also a visual cycle modulator, capable of regulating visual cycle activity by inhibiting retinol isomerization, and holds potential for studying vision disorders such as age-related macular degeneration (AMD)[1][2][3][4]. | [in vivo]
Emixustat (1-10 mg/kg, oral administration, single dose, or twice daily for 6 days; 1 mg/kg, i.p., measurement after 30-60 minutes) reduced cation influx and oxygen consumption in the retinas of brown Norway rats under dark adaptation conditions[3].
Emixustat (0.03-3.0 mg/kg, intravenous injection, once daily for 5 days) inhibits neovascularization and protects the retina in the oxygen-induced retinopathy mouse model[4]. | Animal Model: | Brown norway rats (200-300 g, 3 months old)[3] | | Dosage: | 1, 5 or 10 mg/kg | | Administration: | Oral gavage (p.o.), single dose (1, 10 mg/kg), 2 hours followed by 4 hours of dark adaptation, or twice a day for 6 days (5 mg/kg) | | Result: | Reduced the conductance of the retinal cation channels after dark adaptation.
|
| Animal Model: | Brown norway rats (200-300 g, 3 months old)[3] | | Dosage: | 1 mg/kg | | Administration: | Intravenous injection (i.v.), retinal PO2 was measured 30-60 min later | | Result: | Reduced the oxygen consumption during dark adaptation. |
| Animal Model: | Oxygen-induced retinopathy (OIR) mice model (BALB/c and 129/Sv / C57BL/6 mixed background) | | Dosage: | 0.03, 0.1, 0.3, 1.0, 3.0 mg/kg | | Administration: | Intravenous injection (i.v.), once daily for 5 days | | Result: | Dose-dependently reduced retinal neovascularization. |
| [References]
[1] Kiser PD, et al. Catalytic mechanism of a retinoid isomerase essential for vertebrate vision. Nat Chem Biol. 2015 Jun;11(6):409-15. DOI:10.1038/nchembio.1799 [2] Kubota R, et al. Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina. 2014 Mar;34(3):603-9. DOI:10.1097/01.iae.0000434565.80060.f8 [3] Kubota R, et al. Emixustat Reduces Metabolic Demand of Dark Activity in the Retina. Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4924-4930. DOI:10.1167/iovs.19-28194 [4] Bavik C, et al. Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity. PLoS One. 2015 May 13;10(5):e0124940. DOI:10.1371/journal.pone.0124940 |
|
| Company Name: |
T&W GROUP
|
| Telephone: |
021-61551611 13296011611 |
| Website: |
www.trustwe.com/ |
|